Table 1

Table of gene signatures enriched with genes that are significantly demethylated at promoter regions after 28 d treatment with AGI-6780 (1 μM)

Overlapping genesSignature genesPercentage overlappingGene signature name in MSigDBQ-value
17 186 9% TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_DN* 1.56E−13 
24 414 6% MULLIGHAN_MLL_SIGNATURE_2_UP* 1.81E−13 
23 378 6% MULLIGHAN_MLL_SIGNATURE_1_UP* 1.86E−13 
17 223 8% THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN 3.45E−12 
13 131 10% PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_DN* 1.96E−11 
Overlapping genesSignature genesPercentage overlappingGene signature name in MSigDBQ-value
17 186 9% TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_DN* 1.56E−13 
24 414 6% MULLIGHAN_MLL_SIGNATURE_2_UP* 1.81E−13 
23 378 6% MULLIGHAN_MLL_SIGNATURE_1_UP* 1.86E−13 
17 223 8% THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN 3.45E−12 
13 131 10% PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_DN* 1.96E−11 

Overlapping genes, overlap between gene signature genes and sample genes; signature genes, number of genes in signature; percentage overlapping, percentage of genes in both sample and gene signature; gene signature, gene signature name in MSigDB; Q-value, significance score with multiple hypothesis testing correction applied.

*

Signatures related to leukemia or lymphoma.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal